Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals (VRTX) Stock Price, Analysis & Data
| Bid | n/a |
| Market Cap | 130.67B |
| Revenue (ttm) | 12.59B |
| Net Income (ttm) | 4.41B |
| Beta | 0.30 |
| EPS (ttm) | 17.14 |
| PE Ratio (ttm) | 30.08 |
| Forward PE | 23.63 |
| P/B (ttm) | 6.45 |
| P/S (ttm) | 10.37 |
| Earnings Date | Nov 2, 2026 |
| Ask | n/a |
| Volume | 1,065,093 |
| Avg. Volume (20D) | 1,568,306 |
| Open | 503.87 |
| Previous Close | 505.75 |
| Day's Range | 502.53 - 517.76 |
| 52-Week Range | 374.17 - 546.17 |
| Analyst | Buy |
| Price Target | 570 (10.56%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About VRTX
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of...
Financial Performance
In 2025, Vertex Pharmaceuticals's revenue was 12B, an increase of 8.9% compared to the previous year's 11.02B. Earnings were 3.95B, a decrease of -838.09%.
Financial StatementsAnalyst Forecast
According to 25 analyst ratings, the average rating for VRTX stock is "Buy". The 12-month stock price forecast is 570, which is upside of 10.56% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
